Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000049970 | SCV000918211 | likely pathogenic | Salla disease | 2017-11-27 | criteria provided, single submitter | clinical testing | Variant summary: The SLC17A5 c.719G>A (p.Trp240X) variant results in a premature termination codon, predicted to cause a truncated or absent SLC17A5 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant was found in 13/237362 control chromosomes at a frequency of 0.0000548, which does not exceed the estimated maximal expected allele frequency of a pathogenic SLC17A5 variant (0.0023717). The variant has been reported in at least one affected individual in the literature (Aula_2000). In addition, one clinical diagnostic laboratory/reputable database classified this variant as likely pathogenic. Taken together, this variant is classified as likely pathogenic. |
Labcorp Genetics |
RCV000049970 | SCV000937248 | pathogenic | Salla disease | 2023-09-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 56557). This premature translational stop signal has been observed in individual(s) with sialic acid-storage disease (PMID: 10947946). This variant is present in population databases (rs386833993, gnomAD 0.01%). This sequence change creates a premature translational stop signal (p.Trp240*) in the SLC17A5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC17A5 are known to be pathogenic (PMID: 10581036, 10947946, 15172001). |
Genome- |
RCV000049970 | SCV002027576 | pathogenic | Salla disease | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000049970 | SCV004201202 | pathogenic | Salla disease | 2024-02-28 | criteria provided, single submitter | clinical testing | |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000049970 | SCV000082379 | probable-pathogenic | Salla disease | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |